| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.69% | 84.25% | 84.79% | 80.39% | 83.19% | 82.83% | 84.59% | 83.88% | 82.87% | 82.28% | 77.88% | 71.58% |
| Operating Margin | 17.21% | 27.00% | 24.90% | -12.80% | -2.50% | -10.82% | -14.99% | -9.06% | -16.37% | -27.98% | -35.70% | -14.08% |
| EBITDA Margin | 19.05% | 28.84% | 29.40% | -5.79% | 4.21% | -2.94% | -8.12% | 0.41% | -5.47% | -15.34% | -22.08% | 1.77% |
| Net Margin | 16.37% | 23.57% | 21.39% | -14.24% | -4.10% | -10.67% | -16.79% | -12.73% | -17.48% | -27.95% | -36.15% | -4.86% |
| Current Ratio | 3.55 | 3.04 | 2.86 | 2.27 | 2.25 | 2.53 | 2.46 | 2.89 | 2.78 | 3.73 | 3.20 | 6.71 |
| Quick Ratio | 3.19 | 2.65 | 2.50 | 1.91 | 1.93 | 2.25 | 2.20 | 2.63 | 2.46 | 3.43 | 3.03 | 6.32 |
| Debt / Equity | 0.00 | — | 0.24 | 0.28 | 0.27 | 0.26 | 0.26 | 0.24 | 0.23 | 0.23 | 0.27 | 0.26 |
| ROE | 13.28% | 25.06% | 29.58% | -15.16% | -4.33% | -10.39% | -18.11% | -11.89% | -13.13% | -17.23% | -17.28% | -2.15% |
| ROA | 9.72% | 17.86% | 16.65% | -8.06% | -2.38% | -5.69% | -10.89% | -7.63% | -8.79% | -12.07% | -12.24% | -1.56% |
| Asset Turnover | 0.59 | 0.76 | 0.78 | 0.57 | 0.58 | 0.53 | 0.65 | 0.60 | 0.50 | 0.43 | 0.34 | 0.32 |
| Book Value / Share | 10.78 | 8.66 | 7.09 | 6.38 | 6.91 | 6.72 | 6.91 | 7.55 | 7.84 | 7.98 | 8.81 | 9.62 |
Alkermes plc is an Ireland-based, fully integrated global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience. It specializes in treatments for serious mental illnesses, addiction, schizophrenia, bipolar I disorder, alcohol and opioid dependence, and sleep disorders such as narcolepsy and idiopathic hypersomnia. Key marketed products include Vivitrol for alcohol and opioid dependence, Aristada and Aristada Initio as long-acting injectables for schizophrenia, Lybalvi combining olanzapine and samidorphan for schizophrenia and bipolar I disorder, and manufacturing and royalty agreements for products like Invega long-acting formulations and Vumerity for multiple sclerosis. Alkermes employs proprietary technologies such as NanoCrystal, extended-release microsphere, and LinkeRx platforms to create competitively advantaged therapies. Its investigational pipeline features alixorexton, an oral orexin 2 receptor agonist advancing in phase 2 and 3 studies for narcolepsy types 1 and 2 and idiopathic hypersomnia, alongside other candidates like once-nightly sodium oxybate formulations. With R&D in Waltham, Massachusetts, and manufacturing in Wilmington, North Carolina, Alkermes plc plays a vital role in addressing unmet needs in psychiatric and neurological disorders through patient-inspired science and specialized commercial infrastructure. Founded in 1987 and headquartered in Dublin, Ireland, it serves healthcare and life sciences sectors worldwide.